Day Zero Diagnostics Inc News Today

Inflammatix Inc. received U.S. FDA breakthrough device designation for its Triverity acute infection and sepsis test system, which produces three readouts that could help emergency physicians quickly determine the proper course of treatment.

The time to diagnosis of sepsis infection to a patient in the hospital can be critical, with underdiagnosis resulting in rapid deterioration, risk of organ damage and need for readmission, and overdiagnosis leading to the avoidable and sometimes serious health consequences of overtreating patients with broad-spectrum antibiotics.

/PRNewswire/ -- Day Zero Diagnostics Inc. (DZD), an infectious disease diagnostics company harnessing the power of whole-genome sequencing and AI to combat the...

More than 1,000 of the job commitments are outside of Boston and Cambridge, including Modernas Norwood facility, which received $3.135 million.

/PRNewswire/ -- Day Zero Diagnostics Inc., an infectious disease diagnostics company utilizing genome sequencing and machine learning to combat the rise of...

/PRNewswire/ -- Day Zero Diagnostics Inc., an infectious disease diagnostics company utilizing genome sequencing and machine learning to combat the rise of...

/PRNewswire/ -- Artificial Intelligence (AI) in Medical Diagnostics Market is projected to grow from USD 1.0 billion in 2022 to USD 5.5 billion by 2027, at a...

CHICAGO, Oct. 5, 2022 /PRNewswire/ -- Artificial Intelligence (AI) in Medical Diagnostics Market is projected to grow from USD 1.0 billion in 2022 to USD 5.5 billion by 2027, at a CAGR of 39.9%

/PRNewswire/ -- Day Zero Diagnostics Inc., an infectious disease diagnostics company utilizing genome sequencing and machine learning to combat the rise of...

Boston, MA (PRWEB) April 11, 2022 -- Boston—April 11, 2022—Day Zero Diagnostics, Inc., an infectious disease diagnostics company using genome sequencing and